is this new clinical trial looking to see how adding pluvicto to SOC works for naive hormone sensitive metastatic or metastatic castrate resistant patients? If you showed some psma avid tumor growth on a psma pet scan, when is optimal time to use this newer treatment, assuming you can get Pluvicto? By using Pluvicto to eradicate psma avid pca, would this just leave negative or non psma avid pca?
As we are faced with a conundrum. , With so many pca treatment plans available now, the question is what is optimal treatment plan to choose to get best outcome? Will better data analytics help MO’s make better decisions on treatment plans rather than using chatgpt?